SELLAS Life Sciences Group Inc (SLS): Next-Year EPS Estimate 28.57%
As of 2026-06-04, SELLAS Life Sciences Group Inc (SLS) has a next-year EPS growth estimate of 28.57%.
On 2026-05-14, analyst consensus for SLS's next-year EPS growth shifted from 42.86% to 28.57% — a negative change of 14.29 percentage points. The revised estimate has been sustained across 16 subsequent trading sessions. Current-year growth is projected at 16.00%.
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 28.57%
- EPS growth this year
- 16.00%
- EPS next quarter (est)
- -$0.05
- Last price
- $9.04
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-06-04 | 28.57% | 16.00% | -$0.05 | $9.04 |
| 2026-06-03 | 28.57% | 16.00% | -$0.05 | $8.19 |
| 2026-06-02 | 28.57% | 16.00% | -$0.05 | $8.33 |
| 2026-06-01 | 28.57% | 16.00% | -$0.05 | $9.07 |
| 2026-05-31 | 28.57% | 16.00% | -$0.05 | $9.31 |
| 2026-05-28 | 28.57% | 16.00% | -$0.05 | $9.18 |
| 2026-05-27 | 28.57% | 16.00% | -$0.05 | $8.58 |
| 2026-05-26 | 28.57% | 16.00% | -$0.05 | $8.12 |
| 2026-05-25 | 28.57% | 16.00% | -$0.05 | $7.78 |
| 2026-05-24 | 28.57% | 16.00% | -$0.05 | $7.78 |
| 2026-05-21 | 28.57% | 16.00% | -$0.05 | $7.56 |
| 2026-05-20 | 28.57% | 16.00% | -$0.05 | $8.97 |
| 2026-05-19 | 28.57% | 16.00% | -$0.05 | $7.59 |
| 2026-05-18 | 28.57% | 16.00% | -$0.05 | $7.29 |
| 2026-05-17 | 28.57% | 16.00% | -$0.05 | $7.08 |
| 2026-05-14 | 28.57% | 16.00% | -$0.05 | $7.42 |
| 2026-05-13 | 42.86% | -12.00% | -$0.07 | $6.50 |
| 2026-05-12 | 42.86% | -12.00% | -$0.06 | $5.22 |
| 2026-05-11 | 42.86% | -12.00% | -$0.06 | $5.25 |
| 2026-05-10 | 42.86% | -12.00% | -$0.06 | $5.01 |
| 2026-05-07 | 42.86% | -12.00% | -$0.06 | $4.93 |
| 2026-05-06 | 42.86% | -12.00% | -$0.06 | $5.15 |
| 2026-05-05 | 42.86% | -12.00% | -$0.06 | $4.87 |
| 2026-05-04 | 42.86% | -12.00% | -$0.06 | $5.02 |
| 2026-05-03 | 42.86% | -12.00% | -$0.06 | $4.93 |
| 2026-04-30 | 42.86% | -12.00% | -$0.06 | $4.95 |
| 2026-04-29 | 42.86% | -12.00% | -$0.06 | $4.67 |
| 2026-04-28 | 42.86% | -12.00% | -$0.06 | $4.88 |
| 2026-04-27 | 42.86% | -12.00% | -$0.06 | $4.88 |
| 2026-04-26 | 42.86% | -12.00% | -$0.06 | $4.46 |
Recent News
- Inventiva Builds Up Leadership Team Ahead of Potential CommercializationExec Edge
- These 16 stocks are a short seller's dream - likely losers no matter what the market doesMarketWatch
- SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate UpdateGlobeNewswire
- SELLAS Life Sciences to Present Preclinical Data Highlighting Potent Activity of SLS009 in AML at the 2026 AACR ConferenceGlobeNewswire
- SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009GlobeNewswire
- What's Going With SELLAS Life Sciences Stock On Wednesday?Benzinga
Screen Performance
Aggregate stats across all 1761 tickers our top-EPS-revision screen has flagged over the past 64 days.
- Median return since detection
- +5.1%
- % of tickers in the green
- 62%
- Median return on winners
- +17.5%
- Large revisions captured
- 746
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Frequently Asked Questions
What is SELLAS Life Sciences Group Inc's next-year EPS growth estimate?▾
As of 2026-06-04, SELLAS Life Sciences Group Inc (SLS) has a next-year EPS growth estimate of 28.57%, based on analyst consensus.
When was the latest EPS estimate revision for SLS?▾
The most recent revision occurred on 2026-05-14, when analysts adjusted the next-year EPS growth estimate from 42.86% to 28.57%.
What sector and industry does SELLAS Life Sciences Group Inc belong to?▾
SELLAS Life Sciences Group Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. SLS appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. SELLAS Life Sciences Group Inc (SLS) appears here because it was detected by our daily top-EPS-revision-performer screen.
← All reports